Regio Zuid-Holland | PRO CellecT

Despite significant advances made over the last years in improving the survival of cancer patients, there are still multiple solid cancer types that are currently hard-to-treat. Among a small number of treatment options, TCR-modified T-cells play an attractive role and TCR gene-engineered T-cells have already demonstrated significant benefits in patients. Despite these successes, the momentum of TCR based T-cell therapy is challenged. Pan Cancer T aims to tackle these challenges using a proprietary TCR based T-cell therapy with a unique target selection platform and dual approach, including optimal fitting TCRs and immunosuppressive strategies. ..To date, Pan Cancer T leveraged this platform to identify 32 antigen targets, further called PCTs. These PCTs are exclusively present in 15 currently hard-to-treat cancers, including breast cancer; glioblastoma; kidney renal cell carcinoma; and pancreatic adenocarcinoma. Pan Cancer T’s approach showed in vitro proof-of-concept for all identified PCTs and pre-clinical research on TNBC and melanoma has provided us with early validation to further invest and build a successful company with our platform technology. In parallel, we aim to exploit our other highly promising targets to tackle the unmet patient needs and improve our portfolio value. ..However, currently it is unclear what the optimal strategy to market is. We need to select the right target for the right indication taking the right approach, because such drug development trajectories are time-consuming and costly. As such, a feasibility project is needed to define the optimal development plan, giving insight into the commercial feasibility of the other PCTs in terms of medical need, market characteristics and trends, patent and competitive landscape. The PRO-CellecT project allows us to define a strategic roadmap for our products, thereby maximizing value and reducing barriers and risks.